ESMO 2022 | sciencenewsnet.in

Breaking News

FAU Researchers Receive $1M in FDOH Grants to Fight Alzheimer’s Disease

Xylyx Bio announces exclusive license agreement with Vanderbilt University for donor organ rehabilitation asset

4C Medical’s AltaValve System Secures Dual FDA Breakthrough Device Designations, Expediting Patient Access to Advanced Mitral Valve Therapies

Sonic Youth’s Lee Ranaldo to receive Doctor of Music degree from Binghamton University

Biomarker found to help identify cells that can repair damaged blood vessels

Swarms of miniature robots clean up microplastics and microbes, simultaneously (video)

Honoring Oncology Nurses at the State’s Only NCI-designated Comprehensive Cancer Center

NeuroTherapia Receives Grant from Alzheimer’s Association for Development of First-in-Class Drug for Alzheimer’s Disease

Psychosis Care Deserves Attention During Mental Health Awareness Month

‘Mathematical microscope’ reveals novel, energy-efficient mechanism of working memory that works even during sleep

08 May, 2024

Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

September 12, 2022 sarah JonasResearch Results

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2022.

HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment

September 11, 2022 sarah JonasResearch Results

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.